Evidence map›Paper›PMID 35482838›Full record

ReviewCirculation research2022

Novel Approaches to Imaging the Pulmonary Vasculature and Right Heart.

Fawaz Alenezi, Taylor A Covington, Monica Mukherjee, Stephen C Mathai, Paul B Yu, Sudarshan Rajagopal

Abstract readReview
In one paragraph

Review in Circulation research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Observational
  9. Novel Strategies in Diagnosing Heart Failure with Preserved Ejection Fraction: A Comprehensive Literature Review.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2024
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fawaz AleneziDivision of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC (F.A., S.R.).
Taylor A CovingtonCardiovascular Research Center, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA (T.A.C., P.B.Y.).
Monica MukherjeeJohns Hopkins Division of Cardiology, Baltimore, MD (M.M.).ORCID 0000-0001-6088-0773
Stephen C MathaiJohns Hopkins Division of Pulmonary and Critical Care Medicine, Baltimore, MD (S.C.M.).ORCID 0000-0003-3188-7209
Paul B YuCardiovascular Research Center, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA (T.A.C., P.B.Y.).ORCID 0000-0003-2145-4944
Sudarshan RajagopalDivision of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC (F.A., S.R.).ORCID 0000-0002-3443-5040

Funding

Anastrozole in Pulmonary Arterial Hypertension (AIPH2) - CCC (Lead)R01HL134905 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KAWUT, STEVEN M · 2017 to 2021
$5.5M
Novel probes of BMP and TGF-beta signaling and functionR01AR057374 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI YU, PAUL B · 2010 to 2023
$4.5M
Biasing CXCR3 Signaling to Modulate the Inflammatory ResponseR01GM122798 · NIGMS · DUKE UNIVERSITY · PI RAJAGOPAL, SUDARSHAN · 2017 to 2025
$3.2M
Xenon MRI in Pulmonary HypertensionR01HL153872 · NHLBI · DUKE UNIVERSITY · PI DRIEHUYS, BASTIAAN, RAJAGOPAL, SUDARSHAN K · 2021 to 2024
$2.9M
Context-specific angiogenic signaling in the pulmonary vasculatureR01HL159443 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI YU, PAUL B · 2021 to 2024
$2.4M
Molecular imaging of angiogenic activity in pulmonary arterial hypertensionR01HL131910 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI YU, PAUL B · 2016 to 2018
$2.3M
Hopkins Clinical Center for Pulmonary Vascular Disease Phenomics ProgramU01HL125175 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI HASSOUN, PAUL M., MATHAI, STEPHEN C · 2015 to 2019
$1.1M
NHLBI NIH HHS R01 HL131910NHLBI NIH HHS R01 HL134905NHLBI NIH HHS R01 HL153872NHLBI NIH HHS R01 HL159443NHLBI NIH HHS U01 HL125175NIAMS NIH HHS R01 AR057374NIGMS NIH HHS R01 GM122798
6 · The paper itself

Abstract

There is an increased appreciation for the importance of the right heart and pulmonary circulation in several disease states across the spectrum of pulmonary hypertension and left heart failure. However, assessment of the structure and function of the right heart and pulmonary circulation can be challenging, due to the complex geometry of the right ventricle, comorbid pulmonary airways and parenchymal disease, and the overlap of hemodynamic abnormalities with left heart failure. Several new and evolving imaging modalities interrogate the right heart and pulmonary circulation with greater diagnostic precision. Echocardiographic approaches such as speckle-tracking and 3-dimensional imaging provide detailed assessments of regional systolic and diastolic function and volumetric assessments. Magnetic resonance approaches can provide high-resolution views of cardiac structure/function, tissue characterization, and perfusion through the pulmonary vasculature. Molecular imaging with positron emission tomography allows an assessment of specific pathobiologically relevant targets in the right heart and pulmonary circulation. Machine learning analysis of high-resolution computed tomographic lung scans permits quantitative morphometry of the lung circulation without intravenous contrast. Inhaled magnetic resonance imaging probes, such as hyperpolarized 129Xe magnetic resonance imaging, report on pulmonary gas exchange and pulmonary capillary hemodynamics. These approaches provide important information on right ventricular structure and function along with perfusion through the pulmonary circulation. At this time, the majority of these developing technologies have yet to be clinically validated, with few studies demonstrating the utility of these imaging biomarkers for diagnosis or monitoring disease. These technologies hold promise for earlier diagnosis and noninvasive monitoring of right heart failure and pulmonary hypertension that will aid in preclinical studies, enhance patient selection and provide surrogate end points in clinical trials, and ultimately improve bedside care.

Indexed as

Heart FailureHypertension, PulmonaryHumansPulmonary CirculationXenon IsotopesXenon-129Xenon Isotopescomputed tomographyhemodynamicsmagnetic resonance imagingpulmonary hypertensionpulmonary vasculatureright ventriclexenon MRI

Identifiers

PMID35482838
PMCPMC9060389

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.